DOPAMINE

1|Page
CREATED BY- JIGAR PRAJAPATI(AMCMET)

PUBLISHED ON-JULY 2022

ALL RIGHTS RESERVED

PREFACE
 THE QUESTIONS WERE ASKED IN GUJARAT UNIVERSITY EXAMINATION
FROM YEAR 2004-2022

 THE QUESTIONS ARE ARRANGED BY THEIR TOPICS AND SECTIONS.

 SIGN(*) INDICATES THAT QUESTIONS WERE ASKED AS 6 MARKS

QUESTIONS IN PSM AND 5 MARKS QUESTIONS IN OPTHALMOLOGY,ENT
AND FORENSIC MEDICINE.

 YEAR-I PATTERN SHOWS EXAMINATION OF MAJOR BATCH.

 YEAR-II PATTERN SHOWS EXAMINATION OF MINOR BATCH.

THANK YOU
BY,

JIGAR PRAJAPATI

Mo.-8238520773

AMC MET MEDICAL COLLEGE(LG HOSPITAL),AHMEDABAD

2|Page
PREVENTIVE
AND SOCIAL
MEDICINE
PAPER-I

3|Page
1 MAN AND MEDICINE
TOWARDS HEALTH FOR ALL
JOHN SNOW(2016-I*,2016-II)

2 CONCEPT OF HEALTH AND

DISEASE
VARIABLES(2005-I)

INTERNATIONAL CLASSIFICATION OF DISEASES(2010-I,2015-I)

HUMAN DEVELOPMENT INDEX(2006-I*,2013-I*,2016-I*,2017-I*)

NATURAL HISTORY OF DISEASE(2006-I*,2019-I*)

EPIDEMIOLOGICAL TRAID(2006-I*2008-I,2012-II*,2017-II)

SPIRUTIALITY AND HEALTH(2004-II)

SOCIAL AND SPIRUTIAL DIMENSIONS OF HEALTH(2006-I)

WEB OF CAUSATION(2006-II)

INDICATORS OF HEALTH(2009-II*,2008-II)

PRIMORDIAL PREVENTION(2007-I,2010-II,2011-I*,2013-I*,2020-II)

ICEBERG OF DISEASE(2007-I,2009-I,2012-II,2013-II*,2014-II*,2017-II)

MORTALITY INDICATORS(2007-II*)

MORBIDITY MEASURES(2008-II*)

PRIMARY PREVENTION(2007-II,2013-I*,2016-I)

TERTIARY PREVENTION(2005-I*)

LEVELS OF PREVENTION(2008-I*,2009-II,2015-II,2016-II,2017-II*,2018-II*,2021-I*,2022-I)

MODES OF INTERVENTION(2022-I*,2017-II*,2014-I)

4|Page
PQLI(2008-II,2011-II,2015-I,2018-II)

DIMENSIONS OF HEALTH(2009-II*)

DALY(2018-II*,2010-I)

CONTROL ELIMINATION AND ERADICATION OF DISEASE(2010-II)

PUBLIC HEALTH(2011-I)

HEALTH PROMOTION(2011-I)

INDICATORS FOR MONITORING TOWARDS HEALTH FOR ALL(2010-II*)

DEFINE HEALTH WRITE ABOUT INDICATORS OF HEALTH(2020-II)

SPECTRUM OF HEALTH AND DISEASE(2017-I)

SELF CARE IN HEALTH(2006-II)

ECOLOGY OF HEALTH(2006-I)

REHABILITATION(2011-I)

3 PRINCIPLES OF
EPIDEMIOLOGY AND
EPIDEMIOLGICAL METHODS
COLD CHAIN(2004-II,2008-I,2009-I,2009-II,2020-II,2018-I,2021-I)

CASE CONTROL STUDY(2018-II*,2022-I*)

MIGRATION STUDIES(2011-I*)

5|Page
COHORT STUDIES(2008-II,2009-II,2013-I,2017-I*,2020-II*)

EPIDEMIOLOGY USES(2005-I,2009-II*,2012-I*,2013-I*,2014-I,2015-II*,2016-I)

COMMON SOURCE EPIDEMICS(2009-II)

INCUBATION PERIOD(2004-II,2007-II,2012-II*,2014-II*,2019-I)

RELATIVE/ATTRIBUTABLE RISK(2019-II,2007-I,2016-I,2013-I,2017-II,2010-II,2011-I)

CARRIERS(2011-I*,2008-I*,2010-I*)

MODES OF DISEASE TRANSMISSION(2011-II*)

COMMUNITY DIAGNOSIS(2015-II)

INVESTIGATION OF AN EPIDEMIC(2008-I*,2013-I*,2005-I,2016-II,2019-I*,2021-II*,2022-I)

HERD IMMUNITY(2006-II,2012-II,2018-II)

ADVERSE EFFECTS OF IMMUNIZATION(2005-I*,2011-II,2015-I*,2019-II)

SECONDARY ATTACK RATE(2011-II,2014-I,2015-I,2015-II)

CASE CONTROL STUDY VS COHORT STUDY(2006-II*,2021-II)

INCIDENCE AND PREVELANCE OF DISEASE(2010-I*,2013-II,2017-II,2020-II)

ODDS RATIO(2006-II,2011-I,2015-I,2015-II,2017-II,2018-I)

RANDOMIZED CONTROL STUDY(2007-II,2009-I*)

IMMUNIZATION SCHEDUELE(2015-II*,2014-II,2017-II,2005-I,2014-I)

INTERNATIONAL HEALTH REGULATION(2015-I*)

EMPORIATRICS(2007-II,2013-II*)

QUARANTINE AND ISOLATION(2006-II*,2012-II,2020-II)

CASE CONTROL STUDY(2011-I*,2012-II,2013-II,2014-I*,2016-II,2018-I)

VACCINES FOR INTERNATIONAL TRAVELLERS(2014-II*)

PROPAGATED EPIDEMIC(2009-I)

EPIDEMIC TYPES(2005-I,2017-I)

EPIDEMIC CURVE(2014-II,2015-I*)

EPIDEMIC TRAID(2019-II*)

6|Page
IMMUNOGLOBULINS(2009-II)

SURVILLEANCE(2010-I*,2015-I)

SOCIAL INTERVAL(2016-I)

TIME TREND IN EPIDEMIOLOGY(2008-II*)

COMMUNITY DIAGNOSIS(2007-II,2018-I,2019-II)

DISINFECTION(2018-I,2012-II,2012-I)

SECULAR TRENDS(2013-II*)

CROSS SECTIONAL AND LONGITUDINALN STUDIES(2010-I)

VACCINE CARRIER(2005-I)

SCREENING OF
DISEASE
SENSITIVITY AND SPECIFICITY(2010-I,2013-I*,2014-II,2020-II,2019-II,2015-II)

CRITERIA FOR SCREENING(2007-I,2010-II)

EVALUATION OF SCREENING TEST(2018-II*)

SCREENING TEST-TYPES AND USES(2011-II,2021-I,2007-II,2017-I)

VALIDITY OF SCREENING TEST(2006-I,2014-I,2016-II*)

ADVANTAGES OF SCREENING TEST2015-II)

LEAD TIME(2011-II)

7|Page
EPIDEMIOLOGY OF
COMMUNICABLE DISEASE
EPIDEMIOLOGY OF COVID 19.ADD A NOTE ON COVID 19 VACCINE(2021-I*)

EPIDEMIOLGY PREVENTION CLINICAL FEATURES AND CONTROL OF COVID 19(2022-I*)

MEASLES-EPIDEMIOLOGY ,PREVENTION AND CONTROL(2008-I2021-II*,2004-I,2013-I)

MONOVALENT POLIO VACCINE(2008-I)

PULSE POLIO IMMUNIZATION(2007-I,2009-II,2010-I,2017-II*,2012-II)

POLIOMYELITIS(2004-II*,2018-II,2019-I*)

ROLE OF IPV IN POLIO ERADICATION(2010-II,2015-II)

BCG VACCINE(2013-II*)

JAPANESE ENCEPHALITIS(2012-II)

DOTS THERAPY(2009-II,2014-I*)

DOTS PLUS/MDR TB(2018-I*,2015-I*,2012-I,2006-I)

VACCINE ASSOCIATED PARALYTIC POLIOMYELITIS(2019-II)

XDR TB(2009-I,2010-I)

JAPANESE ENCEPHALITIS(2012-II)

DOTS THERAPY(2009-II,2014-I*)

DOTS PLUS/MDR TB(2018-I*,2015-I*,2012-I,2006-I)

TUBERCULIN TEST(2009-II)

FOOD POISOINING(2006-I*,2012-I,2017-I*)

CHOLERA(2012-II)

TREATMENT OF MILD DEHYDRATION(2019-I,2021-II)

HEPATITIS B -MODE OF TRANSMISSION,PREVENTION AND CONTROL(2022-I*)

8|Page
HEPATITIS B VACCINE(2009-I,2013-II,2014-I*)

TYPHOID-EPIDEMIOLOGY,CONTROL,PREVENTION(2007-II*,2013-II)

ROTAVIRUS VACCINE/PREVENTION(2018-I,2019-II*)

DENGUE-EPIDEMIOLOGY,CONTROL,PREVENTION(2015-II*,2007-I*,2013-I,2017-I*)

MALARIA-PREVENTION,CONTROL(2012-II)

MALARIA-PRESUMPTIVE TREATMENT IN HIGH RISK AREAS(2011-I,2022-I)

MALARIOMETRIC MEASURES(2008-I*,2019-II,2021-II)

TREATMENT OF MALARIA UNDER NVBDCP(2013-I)

ZIKA VIRUS(2018-I)

PREVENTION AND CONTROL OF ARTHROPOD BORNE DISAESE(2005-I*)

ZOONOTIC DISEASE(2019-II)

MX OF GRADE III DOG BITE(2008-I)

MX OF GRADE II DOG BITE(2013-I)

RABIES VACCINE(2011-I,2016-II*,2022-I)

PEP RABIES(2020-II,2021-I,2019-II*)

MX OF DOG BITE WITH OOZING BLOOD(2019-I)

YELLOW FEVER VACCINE/SPREAD MEASURES(2007-I,2015-II)

LEPROSY IN URBAN AREAS(2016-II)

LEPROSYMULTIDRUG THERAPY(2004-II,2005-I,2006-I,2008-II*,2011-II,2012-II,2014-II,2019-I

PREVENTION AND CONTROL OF LEPROSY(2020-II*)

PREVENTION OF DISABILITY IN LEPROSY(2013-I)

HIV/AIDS PREVENTION AND CONTROL(2008-I,2013-I*,2022-I)

HIV/AIDS PEP(2006-I*)

HIV SENTINEL SURVILLEANCE(2016-I)

HIV/AIS WINDOW PERIOD(2021-II*)

STDs-CONTACT TRACING(2007-I)

9|Page
STDs-SOCIAL FACTORS(2009-I*)

STDs SYNDROMIC APPROACH(2012-I,2013-I)

STD MANAGEMENT(2012-II)

HUMAN PAPILLOMA VIRUS(2010-I*)

TETANUS IMMUNIZATION(2006-I)

SYNDROMIC MX OF VAGINAL DISCHARGE(2019-I*)

EPIDEMIOLOGY AND CONTROL OF TETANUS(2020-II*)

NOSOCOMIAL INFECTIONS(2008-I,2019-II)

SWINE FLU EPIDEMIC(2010-II*)

PREVENTION OF HOSPITAL ACQUIRED INFECTION(2015-I)

CASE DEFINITION OF MUMPS SURVILLEANCE(2015-I)

PREVENTIVE MEASURES FOR DIPTHERIA ,MEASLES AND ARI(2016-II)

HINI INFLUENZA(2021-II)

PREVENTION AND CONTROL OF HUMAN PLAGUE(2017-II)

CONGENITAL RUBELLA SYNDROME(2019-I)

NON COMMUNICABLE DISEASE

ACCIDENTS -EPIDEMIOLOGY,PREVENTION,CAUSES(2004-II,2014-II,2021-II*,2020-II*,2019-II)

MEASUREMENTS IN OBESITY (2004-II,2013-I*)

OBESITY AND ITS PREVENTION(2014-II*,2008-II,2016-II)

HAZARDS OF OBESITY(2020-II,2017-I)

CONTROL MEASURES OF ISCHEMIC HEART DISEASE(2008-I)

CORONARY HEART DISEASE-RISK FACTOR AND PREVENTION(2021-II,2004-II,2014-I)

DIABETES MILLITUS -EPIDEMIOLOGY AND CONTROL(2007-II*)

10 | P a g e
MATURITY ONSET DIABETES MELLITUS(2006-I)

DIABETES MELLITUS-RISK FACTOR(2009-I)

HYPERTENSION PREVENTION(2009-II,2021-I)

PRIMARY EYE CARE(2007-I)

SYNDROME X(2011-I)

ROLE OF HEALTH EDUCATION IN EARLY DETECTION OF CANCER(2010-II*)

SCREENING OF BREAST CANCER(2008-II)

SCREENING FOR CANCER(2018-I*,2019-I)

RULE OF HALVES IN HYPERTENSION(2008-II,2013-I,2021-I)

SCREENING FOR CANCER CERVIX(2015-I)

DANGER SIGNS OF CANCER(2014-II*)

VACCINATION FOR CANCER CERVIX(2019-I)

RISK FACTOR FOR NON COMMUNICABLE DISEASE(2019-II)

TRACKING OF BP(2014-II)

MODIFIABLE AND NON MODIFIABLE RISK FACTOR FOR HYPERTENSION(2020-II,2022-I)

PREVENTIVE MEASURES OF LIFESTYLE RELATED DISEASE(2013-I*)

NUTRITION AND HEALTH

EPIDEMIC DROPSY(2005-I*,2007-I,2008-II*,2018-II)

THIAMINE(2006-I)

ASSESMENT OF NUTRITIONAL STATUS(2018-II*,2007-I*)

VITAMIN A(2005-II,2016-II)

VITAMIN A DEFICIENCY,EFFECTS AND PREVENTION (2007-II,2011-I,2019-II,2020-II*,2021-

II*,2022-I)

VITAMIN A RICH FOODS(2016-I*)

VITAMIN A PROPHYLAXIS(2010-II,2012-I,2013-I,2015-I,2007-I)

LATHRYSIM(2007-II*,2016-II,2017-I)

11 | P a g e
TEST FOR PASTURIZRED MILK(2008-I,2022-I)

PASTURIZATION OF MILK(2021-II,2005-I)

MID DAY MEAL SCHEME(2008-I,2018-I)

KWASHIORKAR(2009-I)

VITAMIN C(2009-II)

MICRONUTRIENT MALNUTRITION(2010-I)

FOOD ADDITIVES AND FOOD FORTIFICATION(2006-I,2006-II)

INDIAN REFERENCE MAN AND WOMEN(2010-I*)

BALANCED DIET(2010-II*,2012-I*,2015-II,2019-I,2021-I*)
NUTRITIONAL SURVILLEANCE(2011-II)

FOOD ADULTERATION(2012-II*)

PREVENTION OF FOOD ADULTERATION ACT(2006-II*,2018-I)

IODINE DEFICINCY DISORDERS(2019-I*,2019-II*,2006-I*,2007-I*,2014-I,2016-I*,2016-II)

ROLE OF IODINE IN DIET(2012-II)

MILK HYGEINE(2012-II,2013-II)

NUTRITIONAL PROBLEMS IN PUBLIC HEALTH(2013-I*)

FOOD HYGEINE2013-I)

FOOD BORNE DISEASE(2005-I)

ROLE OF FIBRE IN DIET(2013-II)

XEROPTHALMIA(2013-II*,2006-II*,2008-I)

NUTRITIONAL ANEMIA(2010-II*,2013-II*,2017-II*,2019-II*)

NUTRITIONAL PROBLEMS OF PUBLIC HEALTH SIGNIFICANCE(2018-I*)

ASSESMENT OF NUTRITIONAL STATUS UNDER FIVE CHILD(2015-II*)

ENDEMIC FLOUROSIS(2015-I*,2018-II)

COMMUNITY NUTRITIONAL PROGRAMME(2011-II*)

EVALUATION OF QUALITY OF PROTEIN IN DIET(2005-II)

12 | P a g e
MEDICINE AND SOCIAL SCEINCE
ACCULTURATION(2009-I,2010-I,2011-I,2008-I)

SOCIAL SECURITY(2005-II,2007-I,2009-I,2022-I,2005-I)

FAMILY(2016-II)

ROLE OF FAMILY IN HEALTH AND DISEASE(2007-I*,2015-II,2017-II)

DEFINE FAMILY .WRITE TYPES OF FAMILY(2007-II)

FUNTIONS OF FAMILY(2011-I*,2011-II)

SOCIAL PROBLEMS(2011-II)

CULTURAL FACTORS IN HEALTH AND DISEASE(2010-I*,2014-I,2015-II*,2017-I,2019-II,2021-I)

SOCIAL FACTORS(2013-I)

SOCIAL PATHOLOGY(2006-II,2014-I*,2008-II)

CONSUMER PROTECTION ACT(2012-I*,2013-I)

INTELLIGENT QUITENT(2008-I,2018-II)

SOCIO ECONOMIC STATUS(2012-I*)

MEDICO SOCIAL WORK(2010-II)

ENVIRONMENT AND HEALTH

DESCRIBE SOURCES ,HARMFUL EFFECT ON HEALTH AND MEASURES FOR PREVENTION AND
CONTROL OF AIR POLLUTION(2021-I*)

INDOOR AIR POLLUTION(2019-II*)

INDICATORS OF AIR POLLUTION(2005-I,2016-II*,2017-I*)

CAUSES,PREVENTIVE AND CONTROL MEASURES OF AIR POLLUTION(2007-II*,2009-I*)

NOISE POLLUTION(2014-II)

CRITERIA FOR SAFE DRINKING WATER(2005-II*)

PREVENTION OF VECTOR BORNE DISEASE(2006-I*)

13 | P a g e
KATA THERMOMETER(2006-I)

NOISE HAZARDS(2006-I*)

HEALTH HAZARDS DUE TO SUB STANDARD HOUSING(2006-II)

METHODS OF PURIFICATION OF WATER ON DOMESTIC SCALE(2007-I*,2008-II,2014-I)

EFFECTS OF RADIATION ON HUMAN BODY/RADIATION HAZARDS(2007-II*,2012-I*,2020-II)

CYCLOP(2007-II)

ANTI LARVAL MEASURES FOR CONTROL OF MOSQUITO(2009-I)

VITAL LAYER OF SLOW SAND FILTER(2009-I,2011-II*)

SANITARY WELL(2009-II,2015-II)

MICROBIOLOGICAL ASPECT OF WATER QUALITY(2010-I)

OVERCROWDING(2010-II,2015-I)

SANITARY LATRINE(2010-II)

ANTIRODENT MEASURES(2010-II*)

GLOBAL WARMING-CAUSES AND PREVENTION(2011-I*,2021-II*,2022-I*)

DESCRIBE POT CHLORINATION AND ITS USES(2006-II,2012-II)

BREAK POINT CHLORINATION(2011-I,2013-I)

CHLORINATION OF WATER(2021-I)

SANITARY BARRIER(2012-I)

HOUSING AND HEALTH(2013-I*)

ORTHOTOLUDINE TEST(2014-II)

SPACE SPRAYING(2014-II)

CROSS VENTILATION(2014-II*)

RAPID SAND FILTER(2014-II,2017-I*)

SEWAGE DISPOSAL(2014-II)

MOSQUITO/VECTOR BORNE DISEASE(2016-I,2008-II*)

PRESUMPTIVE COLIFORM TEST(2013-II)

14 | P a g e
HORROCKS APPRATUS(2018-II)

CORRECTIVE EFFECTIVE TEMPERATURE(2018-II)

MILLEINEUM DEVELOPMENT GOALS

MILLENIUM DEVELOPMENT GOALS AND ITS INDICATORS(2012-I*)

HEALTH INFORMATION AND BASIC MEDICAL

SCEINCE
CENSUS(2005-I,2005-II,2011-I,2011-II,2013-II)

BIAS IN STATISTICS(2005-I,2006-II*)

HISTOGRAM(2005-I,2006-II)

STUDENTS TEST(2006-I)

SAMPLING METHODS(2005-I,2007-I,2008-I*,2011-II,2015-I*,2018-I*,2021-I,2010-I)

NORMAL CURVE(2005-II,2010-I*,2019-II,2013-II,2022-I)

TYPES OF DATA (2008-II*)

METHODS OF DATA PRESENTATIONS(2009-I*,2010-II*,2021-I)

USES OF HEALTH INFORMATION(2009-II*,2013-I)

FREQUENCY POLYGON(2009-II*)

BIRTH AND DEATH REGISTRATIONS ACT OF INDIA(2010-II)

SAMPLE REGISTRATIONS SYSTEM(2016-I,2010-I,2017-I,2017-II)

15 | P a g e
NULL HYPOTHESIS(2011-I)

CHI SQUARE TEST(2012-II,2015-II)

SOURCES OF HEALTH INFORMATION(2014-I*,2016-II,2021-I)

MEASURES OF CENTRAL TENDENCY(2014-I,2016-I*)

CLUSTER SAMPLING(2019-I*,2021-II)

RANDOM SAMPLIMG(2020-II)

16 | P a g e
 PREVENTIVE AND
SOCIAL MEDICINE
PAPER II

17 | P a g e
HEALTH PROGRAMMES IN INDIA
NATIONAL CANCER CONTROL PROGRAMME(2006-I,2006-II)

REPRODUCTIVE AND CHILD HEALTH PROGRAMME(2006-II*,2007-I*,2017-II)

ANEMIA MUKT BHARAT(2018-I)

IMNCI(2008-I,2016-II*,2010-II,2009-I*,2017-I*,)

RCH PHASE II(2017-II*)

VISION 2020(2009-I,2009-II,2010-II,2012-I*)

EMERGENCY OBSTETRIC CARE(2010-II,2014-I*,2018-II,2019-II*)

RNTCP(2011-I*,2011-II*,2004-I,2007-II*,2017-II,2018-II,2016-I*)

MENTAL HEALTH PROGRAMME(2011-II,2016-II,2015-I,2015*II)

INTEGRATED VECTOR CONTROL PROGRMME(2006-II*,2007-II,2017-I,2012-I*,2011-I,

2015-II,2013-II)

CHIRANJEEVIYOJNA(2008-II*)

COUNSELLING IN HIV(2014-II,2010-II)

URBAN MALARIA SCHEME(2009-I)

PREVENTIVE MEASURES UNDER NBCP(2014-II*)

JANANI SHISHU SURAKSHA KARYAKRAM(2012-II,2014-II,2014-I*)

TARGET INTERVENTIONS FOR HIGH RISK GROUPS(2016-I,2019-II)

HEALTH RELATED SUSTAINED DEVELOPMENT GOALS(2016-II*,2016-I*,2017-I,2018-II)

WEEKLY IRON AND FOLIC ACID SUPPLEMENT PROGRAMME(2017-I,2016-I*)

RBSY(2016-I)

MISSION INDRADHANUSH(2021-II)

INTEGRATED COUNSELLING AND TESTING CENTER(2016-I,2017-II*)

NATIONAL LEPROSY ERADICATION PROGRAMME(2017-II*,2005-I*)

NATIONAL AIDS PREVENTION AND CONTROL POLICY(2017-I*,2006-II)

RMNCH+A(2017-I*,2018-II*,2019-II*)

18 | P a g e
INDIAN PUBLIC HEALTH STANDARD FOR SUBCENTER(2019-II)

NATIONAL URBAN HEALTH MISSION(2019-II,2021-II*)

NATIONAL HEALTH MISSION(2014-II*,2021-II*)

ANEMIA CONTROL PROGRAMME AND COMMENT ON SURAKSHIT MATRATVA DIVAS (2021-

II*)

VARIOUS NUTRITIONAL PROGRAMME IN INDIA(2019-I*,2020-II*)

AYUSHMAN BHARAT YOJNA(2021-I*,2018-I*)

MISSION INDRADHANUSH(2021-II)

NATIONAL RURAL HEALTH MISSION(2009-II*,2009-I*,2008-I*)

BEHAVIOR CHANGE COMMUNICATION(2012-I*,2016-I)

RBSK(2014-II,2019-II*)

RKSK(2015-II,2016-I*)

19 | P a g e
DEMOGRAPHY AND FAMILY PLANNING
FERTILITY INDICATORS(2006-I*,2007-I*,2011-II*,2017-I*)

DEMOGRAPHIC CYCLE(2010-II,2011-II*,2013-I*,2014-II,2015-II,2016-II*,2017-I,2019-I,
2020-II,2021-I,2004-I)

SEX RATIO(2010-I,2013-II*,2014-II,2008-II)

DEFINE SEX RATIO AND FACTORS RESPONSIBLE FOR SKEWED SEX RATIO IN INDIA(2021-
I,2021-II*)

EMERGENCY CONTRACEPTION(2010-II*,2016-II,2019-II,2021-II)

POST COITAL CONTRACEPTION(2007-I,2014-I)

ORAL CONTRACEPTIVE(2008-I,2020-II)

CLASSIFICATION OF CONTRACEPTIVE METHODS(2017-II*2021-I*)

FEMALE CONDOM(2016-I)

IUCD(2011-I,2018-II*)

ELIGIBLE COUPLES(2006-I)

MENSTRUAL REGULATION(2012-I)

NON CONTRACEPTIVE METHOD OF POPULATION CONTROL(2009-I*)

INDICATION OF MTP(2021-II,2021-II)

MTP ACT (2008-I*,2014-II*,2015-I*,2017-II*,2018-II,2019-I*)

PEARL INDEX(2010-I,2013-I*,2018-II)

COUPLE PROTECTION RATE(2012-I,2007-I)

NATIONAL POPULATION POLICY(2016-II*,2017-II,2011-II)

POPULATION TREND/CONTROL IN INDIA(2010-I,2011-I*)

POST PARTUM PROGRAMME(2009-II)

DEPENDENCY RATIO(2009-II,2015-I)

UNMET NEED FOR FAMILY PLANNING(2009-II*,2013-II*)

GROSS AND NET REPRODUCTION RATES(2006-II)

20 | P a g e
PREVENTIVE MEDICINE IN OBSTETRICS
,PEDIATRICS AND GERIATRICS
LOW BIRTH WEIGHT-CAUSES,CONTROL AND PREVENTION(2011-I,2013-I,2009-II*,2007-II*)

NEONATAL MORTALITY RATE(2005-I,2007-II,2019-II)

INFANT MORTALITY RATE-CAUSES,PREVENTION, FACTORS AFFECTING(2008-I*,2011-I,2014-

II*,2018-II*,2014-I*,2007-I*,2021-II*)

MATERNAL MORTALITY CAUSES,PREVENTION,FACTORS AFFECTING(2004-II*,2011-II*,2012-

II,2007-II*,2015-II*,2017-I*,2017-II,2016-I,2020-II*)

HIGH RISK INFANTS(2011-II*,2013-I)

AT RISK MOTHER(2005-I,2012-I,2012-II,2021-II)

EXCLUSIVE BREAST FEEDING(2004-II,2018-I*,2021-I)

HEALTH PROBLEMS OF ELDERLY IN INDIA(2011-I,2010-I,2011-I,2011-II,2019-II,2019-I*,2020-

II*,2021-II,2021-I,2007-II*,2008-II)

HEALTH PROBLEMS OF ADOLSCENT(2004-II,2014-I,2007-II)

GROWTH CHART(USES)(2010-II,2017-I,2020-II,2012-I,2015-I, 2013-II,2006-I,2008-I,2007-

II,2021-II)

COMPONENTS OF SCHOOL HEALTH PROGRAMME(2013-I,2020-II,2013-II*,2011-I*,2014-

I,2017-II,2016-II,2007-I,2006-I,2009-I,2015-I)

IMCI(2004-I)

ANTENATAL CARE(2007-I,2008-I,2010-I,2011-I*,2021-I,2021-II)

UNDER FIVE CLINIC(2012-II)

MID DAY MEAL PROGRAMME(2006-II*,2018-II*)

JUVENILE DELIQUENCY(2009-I,2010-I,2007-II)

BABY FRIENDLY HOSPITAL INITIATIVE(2010-I,2015-I,2018-I*)

ARTIFICIAL FEEDING FOR INFANTS/WEANING(2006-I,2020-II)

FACTORS CONTRIBUTING TO UNDER NUTRITION AMONG LESS THAN 5 YEAR CHILDREN(2020-II)

BEHAVIOR PROBLEMS IN CHILDREN(2006-II,2009-II)

21 | P a g e
INTEGRATED CHILD DEVELOPMENT SERVICES(2017-II,2021-II*)

DESCRIBE INDICATORS OF MATERNAL AND CHILD HEALTH CARE .DESCRIBE MEASURES TO

LOWER MATERNAL MORTALITY RATIO(2021-I*)

INFANT AND YOUNG CHILD FEEDING PRACTICES(2021-II)

CAUSES AND PREVENTION OF CONGENITAL MALFORMATION(2008-I*)

CHILD TRAFFICKING(2008-I)

SOCIAL WELFARE(2018-I)

FIVE CLEANS(2016-I)

NEONATAL SCREENING(2018-II)

DISASTER MANAGEMENT
COLOR CODING IN DISASTER MANAGEMENT(2016-I*)

TRIAGE(2016-II)

EPIDEMIOLGICAL SURVILLEANCE AND DISEASE CONTROL DURING DISASTERS(2015-I*)

HEALTH HAZARDS DUE TO FLOODS(2018-II*)

DISASTER MITIGATION(2019-II*)

DISASTER PREPAREDNESS(2009-I,2017-II)

FLOOD RELIEF(2008-II)

22 | P a g e
 OCCUPATIONAL HEALTH
PNEUMOCONIOSIS(2005-I,2011-II,2016-II*,2017-I*)

SILICOSIS(2007-II,2009-II,2013-I,2019-I,2020-II*,2021-II)

ASBESTOSIS(2006-I,2013-II) ANTHRACOSIS(2011-II)

SICKNESS ABSENTEISM(2006-II,2008-I,2015-II)

OCCUPATIONAL HEALTH HAZARDS FACED BY AGRICULTURAL WORKERS(2006-II*,2014-

II*,2021-I)

MEDICAL BENEFITS UNDER ESIS(2009-I,2010-I*,2014-I*,2014-II*,2015-II*,2017-II*,2018-

II,2019-I*,2020-II*,2021-II)

PROVISION FOR WOMEN AND CHILDREN UNDER FACTOTIES ACT(2006-II*)

OCCUPATIONAL HAZARDS(2011-I,2014-I,2015-II*,2016-I,2021-I)

PRE PLACEMENT EXAMINATION(2011-I,2014-I*,2015-I,2016-I*,2019-I)

MEASURES TO PREVENT OCCUPATIONAL DISEASES(2007-I*,2018-II*,2021-I*)

LEAD POISOINING(2007-II*,2010-II,2018-I)

OCCUPATIONAL CANCER(2019-I) , SKIN CANCER(2008-II)

BAGASSOSIS(2009-I) , FARMERS LUNG(2008-I,2018-II)

GENETICS AND HEALTH

GENETIC COUNSELLING(2006-II,2014-I,2015-II,2017-I,2009-I,2007-II)

EUGENICS(2012-I*) , AMNIOCENTESIS(2007-I)

SICKLE CELL ANEMIA(2006-I*,2015-II*)

DESCRIBE PREVENTIVE AND SOCIAL MEASURES OF GENETIC DISORDERS(2021-I)

MULTIFACTORIAL DISORDERS(2013-II)

SEX CHROMOSOME DISORDERS(2016-II)

ROLE OF GENETIC PREDISPOSITION IN COMMON DISORDERS(2014-I)

GENETIC ENGINEERING(2011-II)

23 | P a g e
 MENTAL HEALTH
ALCOHOLISM(2011-I)

SIGNS AND CAUSES OF MENTALLY ILL PERSON(2006-I,2011-I,2014-I)

PREVENTION OF MENTAL ILLNESS(2020-II)

DEPRESSION(2017-I)

DEPENDENCE PRODUCING DRUGS(2013-I,2013-II)

CHARACTERISTICS OF MENTALLY HEALTHY PERSON(2009-I*,2013-I)

TYPES OF MENTAL ILLNESS(2009-II)

SYMPTOMS OF DRUG ADDICTION(2009-I)

PASSIVE SMOKING(2008-I,2021-I)

COMMUNITY APPROACH IN MENTAL HEALTH(2007-II,2007-I)

WHAT ARE WARNING SIGND OF POOR MENTAL HEALTH ,DESCRIBE PREVENTIVE MEASURES
FOR MENTAL HEALTH PROBLEM(2021-I*)

DEFENSE MECHANISM FOR MENTAL HEALTH(2006-II)

COMMUNICATION FOR HEALTH EDUCATION

COMMUNICATION BARIER(2012-II*,2017-I,2016-II,2019-II,2013-II*,2007-I,2021-I*)

TYPES OF COMMUNICATION(2013-I*,2014-I,2010-I,2007-II,2021-I)

PRINCIPLES OF HEALTH EDUCATION(2011-II,2012-I*,2009-I*.2006-I*,2021-I)

PRINCIPLES OF KNOWN TO UNKNOWN IN HEALTH EDUCATION(2011-I,2013-I,2015-II)

COMMUNICATION PROCESS(2005-I*,2017-II)

METHODS IN HEALTH COMMUNICATION(2006-II*,2012-II,2013-II,2018-II*,2020-II*)

APPROACH TO HEALTH EDUCATION(2009-I,2013-I,2013-II,2017-I,2018-I)

COUNSELLING IN HEALTH(2011-II*,2013-I,2014-I,2005-I)

GATHER APPROACH IN COUNSELLING(2021-II)

LECTURE AS TEACHING METHOD(2013-I)

24 | P a g e
HEALTH PLANNING ANG MANAGEMENT
PROGRAMME EVALUATION AND REVIEW TECHNIQUR(PERT)(2007-I,2010-II,2009-II*,2018-II)

NETWORK ANALYSIS(2009-I*,2010-II*)
COST BENEFIT ANALYSIS(2011-I,2021-II)

PLANNING CYCLE(2014-I,2015-II*,2013-II,2017-I*,2017-II,2016-II,2019-II*,2014-I,2019-
I,2020-II)

EVALUATION OF HEALTH SERVICES(2006-I*,2014-I)

PANCHAYAT RAJ(2013-I)

INPUT OUTPUT ANALYSIS(2011-II)

DEFINE MANAGEMENT AND ITS IMPORTANCE IN HEALTH SYSTEM(2013-I)

COST EFFECTIVE VS COST BENEFIT ANALYSIS(2015-II)

NATIONAL HEALTH POLICY 2017(2018-I*)

HEALTH PLANNING ANG MANAGEMENT TARGET AND GOAL(2009-II)

FEMALE HEALTH WORKER(2016-I)

HEALTH CARE SYSTEM IN INDIA(2014-I)

BHORE COMMITTE(2013-I*)

HEALTH CARE OF COMMUNITY

PRINCIPLES OF PRIMARY HEALTH CARE(2011-II,2015-II*,2017-II,2016-II,2019-I,2020-II,2013-
I,2009-II*,2009-I*,2006-II,2017-II)

ELEMENTS OF PRIMARY HEALTH CARE(2007-II,2019-I)

COMMUNITY PARTICIPATION(2014-II,2016-I,2007-I,2008-II)

APPROPRIATE TECHNOLOGY(2008-II*,2012-I,2018-I)

PHC(FUNCTION)(2012-II,2014-II*,2017-II,2013-II)

CHC(2011-I)

ASHA(2008-I,2010-I,2013-II,2016-I*,2014-I*)

25 | P a g e
INDIAN RED CROSS SOCEITY(2007-I,2009-II,2013-II,2017-II)

LEVELS OF HEALTH CARE(2014-I,2021-I)

HEALTH PROBLEMS IN INDIA(2016-I,2017-I*

DUTIES OF MEDICAL OFFICER AT PHC(2007-II,2009-II)

SUB CENTRE(2010-I*,2015-I)

ANGANWADI WORKER(2006-II,2010-I)

MPHW(2010-I*)

ROLE OF NGO IN PUBLIC HEALTH(2018-I)

INTERNATIONAL HEALTH
UNICEF(2006-I,2011-II,2017-I,2015-I*,2013-II,2007-II)

CARE(2009-I,2012-I)

WHO(2010-I,2013-I,2012-II,2014-I*,2015-II,2016-I*,2016-II)

WHO THEME FOR 2016(2018-I)

WHO THEME FOR 2012(2013-I*)

WORLD HEALTH DAY 2010(2010-II)

WORLD HEALTH DAY 2008(2008-II)

26 | P a g e
OPTHALMOLOGY

27 | P a g e
ANATOMY OF EYE
THEROIES OF COLOR VISION(2009-I,2016-I)

DARK ADAPTATION(2015-I)

DIAGRAM OF EYE(2018-I)

REFRACTORY ERRORS
APHAKIA(2005-I,2012-II,2016-II,2011-I)

ASTIGMATISM(2006-I,2012-I,2017-I,2022-I)

MYOPIA(2008-I,2009-I,2013-II,2018-I,2019-I,2020-II)

FUNDUS PICTURE OF HIGH MYOPIA(2006-II,2003-I*)

DEGENERATIVE MYOPIA(2013-I)

TREATMENT OF MYOPIA(2021-I,2003-II*)

HYPERMETROPIA(2008-II,2011-II,2016-I,2019-II)

STRUM CORNOID(2009-II,2010-II)

PRESBYOPIA(2013-II,2018-II,2021-I,2021-II,2022-I)

LASIK(2009-II)

SOFT CONTACT LENS(2004-II)

ADVANTAGES AND DISADVANTAGES OF CONTACT LENS OVER SPECTACLES(2014-II)

28 | P a g e
 CONJUCTIVA
VERNAL CONJUCTIVITIS(2003-II,2006-II,2007-II,2011-I,2014-I,2016-I,2020-II,2021-I*,2022-I)

PTERYGIUM(2006-II,2009-I,2011-II,2013-I,2015-I,2004-II,2003-I*,2021-II,2021-I)

PTERYGIUM AND PSEUDOPTERYGIUM DIFFERNCE(2008-I)

CLASSIFICATION OF TRACHOMA(2003-II)

COMPLICATION OF TRACHOMA(2009-I,2013-II*)

ACUTE MUCOPURULENT CONJUCTIVITIS(2014-I)

OPTHALMIA NEONATORUM(2014-II,2017-II)

PHYLCTENULAR CONJUCTIVITIS(2003-I,2017-II)

MANAGEMENT OF PROGRESSIVE PTERYGIUM(2022-I)

TYPES OF CONJUCTIVITIS(2013-II)

NODULE AT LIMBUS(2009-II)

CORNEA
HYPOPYON CORNEAL ULCER(2005-I,2009-II,2012-II*,2016-I,2018-I)

BACTERIAL CORNEAL ULCER AND MANAGEMENT(2006-I,2020-II*,2022-I*)

FUNGAL CORNEAL ULCER(2011-I,2004-II,2012-I)

VIRAL KERATITIS(2011-II,2021-II,2008-II)

MOORENS ULCER(2006-II,2016-II)

KERATOPLASTY(2008-II,2010-II)

KERATOCONUS(2012-I,2016-I)

ULCUS SERPENS(2011-II)

COMPLICATIONS OF CORNEAL ULCER(2013-I*,2014-II,2019-II)

LAYERS OF CORNEA(2016-II*,2018-II*)

29 | P a g e
CORNEAL TRANSPARENCY AND FACTORS MANTAINING IT(2016-II*,2018-II*2005-I)
HERPES ZOOSTER OPTHALMICUS(2010-II)

HERPES SIMPLEX KERATITIS(2012-II)

DENDRITIC CORNEAL ULCER(2015-I)

BACTERIOLOGY OF CORNEAL ULCER(2014-I*)

CORNEAL DYSTROPHY VS CORNEAL DEGENERATION(2017-II)

SCLERA
EPISLERITIS AND SCLERITIS(2008-I)

STAPHYLOMA(2013-II)

UVEAL TRACT
CLINICAL FEATURES OF IRIDOCYCLITIS(2006-II,2007-II,2009-I,2022-I)

ACUTE IRIDOCYCLITIS(2011-I,2016-II,2018-I,2003-I)

CLASSIFICATION OF UVEITIS(2013-I*,2013-II,2016-I)

TREATMENT OF IRIDOCYCLITIS(2020-II,2021-II*,2021-I)

D/D OF ACUTE RED EYE(2008-II*,2010-II,2021-I*)

ANATOMY OF CILIARY BODY(2009-II*)

INDICATION OF EVISCERATION(2008-II)

30 | P a g e
 LENS
COMPLICATED CATARACT(2006-II,2007-II*,2019-II)

COMPLICATIONS OF CATARACT SURGERY(2009-II,2018-II,2008-II,2021-II*)

CONGENITAL CATARACT(2011-II,2013-I,2018-I,2004-II*,2017-I)

PHACOEMULSIFICATION(2012-II,2016-II,2003-II)

POSTERIOR CAPSULAR OPACIFICATION(2003-II,2016-I)

HYPHEMA(2017-I*,2004-II)

AFTER CATARACT(2005-I*)

SENILE CATARACT(2017-II*,2009-I,2020-II*)

POST OPERATIVE COMPLICATIONS OF CATARACT SURGERY(2006-I*)

SURGICAL STEPS OF MANUAL SMALL INCISION CATARACT SURGERY(2019-I)

ADVANTAGES OF PHACOEMULSIFICATION OVER MSICS(2022-I)

CRYSTALLINE LENS(2017-II*)

FOLDABLE IOL(2017-I)

GLAUCOMA
ACUTE CONGESTIVA GLAUCOMA AND ITS MANAGEMENT(2011-I,2018-I,2007-II,2016-
II,2019-I*,2003-II,2004-II)

ACUTE ANGLE CLOSURE GLAUCOMA (2008-II,2009-I,2012-I)

TREATMENT OF ACUTE ANGLE CLOSURE GLAUCOMA(2014-II,2015-II,2022-I*)

ANATOMY OF ANGLE OF ANTERIOR CHAMBER(2003-I,2009-I*,2012-I*,2016-II*,2019-II*)

GLAUCOMA FIELD DEFECTS(2012-II*,2013-I,2016-II)

OPTIC DISC CHANGES IN CLAUCOMA(2015-II)

PRIMARY OPEN ANGLE GLAUCOMA(2011-I)

BUPTHALMOS(2011-II)

31 | P a g e
SECONDARY GLAUCOMAS(2011-II,2017-I,2017-II)

TREATMENT OF OPEN ANGLE GLAUCOMA(2014-I)

MANAGEMENT AND EXAMINATION OF POAG(2021-II*)

PATHWAY OF AQUEOUS PRODUCTION AND OUTFLOW(2019-II*)

PROVOCATIVE TEST FOR CLOSED ANGLE GLAUCOMA(2005-I)

VITREOUS
VITREOUS HAEMORRHAGE(2018-II)

RETINA
DIABETIC RETINOPATHY(2004-II,2005-I*,2006-I,2011-I,2013-I,2014-I,2018-I,2021-II)

RETINOBLASTOMA(2006-I*,2010-II,2011-II,2012-II*,2019-II)

RETINITIS PIGMENTOSA(2006-II,2016-II,2017-I,2004-II*)

RETINAL DETACHMENT(2007-II,2017-II)

CENTRAL SEROUS RETINOPATHY(2009-II,2012-II)

LAYERS OF RETINA(2015-II*,2017-I*)

HYPERTENSIVE RETINOPATHY(2016-I,2017-I)

EALES DISEASE(2008-I)

CHERRY RED SPOT(2009-I)

NORMAL FUNDUS OF EYE(2014-I*)

DIFFERENT METHODS OF SEALING RETINAL BREAKS(2003-I)

SWINGING FLASH LIGHT TEST(2017-II)

FUNDUS FINDIND IN DIABETES MELLITUS(2003-II*)

PHOTOCOAGULATION(2019-I*)

CLASSIFICATION OF DIABETIC RETINOPATHY(2021-I)

32 | P a g e
 NEURO-OPTHALMOLOGY
PAPILLOEDEMA(2012-II,2003-I,2013-I,2015-II,2019-II,2014-I)

OPTIC NEURITIS(2007-II*,2018-I)

LESIONS OF VISUAL PATHWAY(2005-I)

PAPILLOEDEMA AND PAPILLITIS(2008-I)

A-R PUPIL(2008-II)

PUPILLARY PATHWAY OF LIGHT REFLEX(2015-II)

BITEMPORAL HEMIANOPIA(2009-I)

AMBYLOPIA(2013-II)

TOXIC AMBYLOPIA(2013-I)

CAUSES OF LEUKOCORIA(2012-I,2016-I)

STRABISMUS
PARALYTIC SQUINT(2006-I,2010-II)

EXTRAOCULAR MUSCLES(2014-II,2015-I*,2015-II*)

PARALYTIC SQUINT(2006-I,2010-II)

BINOCULAR VISION(2008-I)

UNIOCULAR DIPLOPIA(2009-II)

BINOCULAR DIPLOPIA(2015-I)

HETEROPHORIA(2017-II)

WORTH FOUR DOT TEST(2019-I)

MADDOX ROD TEST(2021-I)

COVER TEST(2003-I*)

33 | P a g e
 EYELIDS
BLEPHARITIS(2005-I,2006-II,2008-II)

ENTROPION(2006-I,2007-II,2010-II,2013-I,2004-II)

ECTROPION(2011-II,2013-II)

CHALAZION(2012-II,2019-II,2016-I,2003-II)

ANATOMY OF EYELID(2014-I*,2016-I*)

TYPE OF PTOSIS(2017-II,2021-II)

INTERNAL HORDOLEUM(2018-I,2018-II)

STYE(2021-I)

ENUMERATE DISEASE OF EYELIDS(2021-II)

TREATMENT OF TRICHIASIS(2019-I)

LACRIMAL APPARATUS
CONGENITAL DACROCYSTITIS(2005-I*,2006-II,2015-I)

ACUTE DACROCYSTITIS(2007-II,2013-II)

ANATOMY OF LACRIMAL PASSAGE(2011-II*,2014-II*)

DACRYOCYSTORHINOSTOMY(2006-I)

NASOLACRIMAL DUCT(2009-II)

CHRONIC DACROCYSTITIS(2011-I)

SCHRIMER TEST(2014-II*)

DRY EYE(2012-I)

NASOLACRIMAL DUCT BLOCK(2012-I)

TEAR FILM(2014-II)

SAC SYRINGING(2003-II)

34 | P a g e
 ORBIT
ORBITAL CELLULITIS(2012-I,2012-II,2018-II,2022-I)

CRICKET BALL INJURY (2016-II*)

CAVERNOUS SINUS THROMBOSIS(2013-I)

THYROID OPTHALMOLOGY(2006-I,2007-II,2021-I)

OCULAR INJURIES
TREATMENT OF CHEMICAL INJURIES OF EYE(2014-II)

CONCUSSION INJURY(2015-II)

ALKALI INJURIES TO EYE(2016-I*)

DESCRIBE MECHANISM OF CLOSED GLOBE INJURY AND ITS OPTHALMIC EFFECTS(2017-II*)

INTRAOCULAR FOREIGN(2018-II)

OCULAR MANIFESTATION OF BLUNT INJURY TO EYE(2018-II)

SYMPATHETIC OPTHALMITIS(2005-I)

OCULAR PHARMACOLOGY
ANTI FUNGAL AGENTS(2009-II*,2016-I*,2018-[*,2020-II)
ANTI VIRAL AGENTS(2009-I*,2016-II*,2017-I*)

TIMOLOL MALEATE(2008-II,2013-II,2022-I*)

ANTI GLAUCOMA DRUGS(2010-II*,2016-I*)

MYDRIATIC-CYCLOPLEGICS(2011-I*,2017-II*,2019-II*,2016-I,2021-I*)

ATROPINE(2003-I,2015-I*,2022-I*)

XYLOCAINE(2011-II*)

PILOCARPINE(2018-II*)
MITOMINIC (2012-I*)

35 | P a g e
 SYSTEMIC OPTHALMOLOGY
VITAMIN A DEFECIENCY(2005-I,2006-II*,2017-I,2007-II,2013-II,,2016-II,2019-II*,2020-II)

WHO CLASSIFICATION OF VITAMIN A DEFECIENCY(2014-II)

OCULAR MANIFESTATION OF HIV INFECTION(2014-II,2018-II)

OCULAR COMPLICATIONS OF DIABETES MELLITUS(2015-I)

OCULAR MANIFESTATIONS IN TB(2019-II)

COMMUNITY OPTHALMOLOGY
VISION 2020(2019-II)

EYE DONATION(2012-I)

EYE BANKING(2020-II)

CLINICAL METHODS IN OPTHALMOLOGY

COMPUTER VISION SYNDROME(2014-I,2019-I)

PERIMETRY(2018-II)

TONOMETRY(2020-II)

SCHIOTZ TONOMETER(2015-II)

CAUSES OF MIOSIS(2015-I)

SNELLEN VISION CHART(2006-I)

MYDRIASIS(2008-I)

DARK ROOM PROCEDURES

SLIT LAMP EXAMINATION(2016-II)

RETINOSCOPY(2015-II,2021-II)
GONIOSCOPY(2015-II*)
PIN HOLE(2008-II)
DIRECT OPTHALMOSCOPY(2018-II)
36 | P a g e
ENT

37 | P a g e
 EAR
ANATOMY OF EAR
MEDIAL WALL OF MIDDLE EAR(2004-II*,2007-I*,2012-I*,2017-I*)

SINUS TYMPANI(2008-I*,2017-II,2018-I)

TYMPANIC MEMBRANE(2007-II*,2019-I*)

ANATOMY OF MIDDLE EAR(2016-I*,2019-II*)

ANATOMY OF INNER EAR(2018-II*,2021-II*)

MIDDLE EAR CLEFT(2005-I*)

EUSTACHIAN TUBE(2018-I*)

PERIPHERAL RECEPTORS AND PHYSIOLOGY OF AUDIRORY AND

VESTIBILAR SYSTEM
ORGAN OF CORTI(2011-I,2013-I*)

TRANSFORMER MECHANISM OF MIDDLE EAR(2008-I)

IMPENDANCE MATCHING MECHANISM(2012-I*,2018-II*)

PHYSIOLOGY OF HEARING(2014-I*,2015-II*)

THEORIES OF HEARING(2017-II*)

ASSESMENT OF HEARING
RINNES TEST(2012-II,2013-II,2018-I)

TYMPANOMETRY(2008-II,2017-II)

AUDIOMETRY(2009-I)

TYMPANOGRAM(2009-II)

TUNNING FORK TEST(2019-I,2021-II)

PURE TONE AUDIOGRAM(2021-I)

38 | P a g e
 HEARING LOSS
TYMPANOPLASTY(2006-I*,2008-II,2011-I)

D/D OF CONDUCTIVE DEAFNESS(2005-I)

SUUDEN SENSONEURAL HEARING LOSS(2014-I,2016-I)

OTOTOXICITY(2013-I,2018-I)

DISCUSS SOUND CONDUCTING MECHANISM AND DIFFERENCE BETWEEN CONDUCTIVE AND

SENSORY NEURAL HEARING LOSS(2020-II*)

ASSESMENT OF VESTIBULAR FUNCTION

FISTULA TEST(2006-I)

CALORIC TEST(2021-II)

FITZGERALD HALLPIK TEST(2012-I)

DISEASE OF EXTERNAL EAR

MALIGNANT OTITIS EXTERNA(2009-II,2010-II,2013-II,2018-I,2010-I)

PREAURICULAR SINUS(2005-I*,2016-I)

AURAL SYRINGING(2007-II,2020-II)

OTOMYCOSIS(2010-I,2015-I,2019-II)

EAR WAX(2022-I)

KERATOSIS OBTURANS(2018-II)

NECROTIZING EXTERNAL OTITIS(2016-II)

39 | P a g e
 DISORDERS OF MIDDLE EAR
NON SUPPURATIVE OTITIS MEDIA(2004-II,2009-I*)

SEROUS OTITIS MEDIA(2006-I,2018-II,2016-II,2021-I,2007-II,2009-II*)

MANAGEMENT OF SEROUS OTITIS MEDIA(2007-I,2014-I*)

OTITIC BAROTRAUMA(2015-I,2016-I)

RETRACTED TYMPANIC MEMBRANE(2016-I)

ACUTE SUPPURATIVE OTITIS MEDIA(2007-II,2019-I*)

CHOLESTEATOMA AND CHRONIC OTITIS MEDIA

CLINICAL FEATURES OF DANGEROUS CSOM(2004-II)

CHOLESTEATOMA(2008-I,2009-II)

SAFE OTITIS MEDIA(2007-I)

DIFFERNCE BETWEEN SAFE AND UNSAFE CSOM(2010-II)

DESCRIBE THEORIES OF CHOLESTEATOMA AND BACTERIOLOGY OF OTITIS MEDIA(2014-II*)

COMPLICATIONS OF SUPPURATIVE OTITIS MEDIA

LATERAL SINUS THROMBOSIS(2008-I)

OTITIC HYDROCEPHALUS(2011-II)

ACUTE MASTOIDITIS(2012-II,2013-II*)

EXTRACRANIAL COMPLICATIONS OF OTITIS MEDIA(2021-I*)

EXTRACRANIAL COMPLICATIONS AND MANAGEMENT OF VARIOUS INTRACRANIAL

COMPLICATIONS(2012-II*)

40 | P a g e
 OTOSCLEROSIS
OTOSCLEROSIS(2006-I*,2011-II)

CAHARTS NOTCH(2022-I,2018-I)

OTOSPONGIOSIS(2011-I*)

FACIAL NERVE AND ITS DISORDERS

BELL PALSY(2006-I,2008-II*,2010-I,2012-I,2014-I,2015-II)

RAMSAY HUNT SYNDROME(2012-II)

ENUMERATE BRANCHES OF FACIAL NERVE ,DESCRIBE C/F AND MANAGEMENT OF BELLS

PALSY(2021-II*

MEINERS DISEASE
MEINNERS DISAESE(2010-I*,2013-I*)

HENNEBERT SIGN(2013-I)

REHABILITATION OF HEARING IMPAIRED

COCHLEAR IMPLANTS(2008-II,2014-II,2015-II)

HEARING AIDS(2009-I)

ACOUSTIC NEUROMA
ACOUSTIC NEUROMA(2014-II)

41 | P a g e
 NOSE
ANATOMY OF NOSE
LATERAL WALL OF NOSE(2004-II*,2007-II*,2015-I*,2016-II*,2018-I*,2018-II*)

DESCRIBE OSTEOMEATAL COMPLEX AND FESS(2016-II*)

ENDOSCOPIC ANATOMY OF LATERAL WALL OF NOSE(2017-II*)

ANATOMY OF NOSE AND ITS FUNCTION(2017-I*)

PHYSIOLOGY OF NOSE
FUNCTIONS OF NASAL CAVITY(2008-I*,2016-I*)

PHYSIOLOGY OF NOSE (2014-I*)

DISEASES OF EXTERNAL NOSE AND NASAL VESTIBULE

VESTIBULITIS(2016-I,2017-I)

NASAL SEPTUM AND ITS DISEASES

ANATOMY OF NASAL SEPTUM(2014-II,2015-II*)

SEPTAL PERFORATION(2010-I)

MANAGEMENT OF DEVIATED NASAL SEPTUM(2015-II*)

SEPTAL ABSCESS(2014-I)

ANATOMY OF NASAL SEPTUM AND DESCRIBE NASAL SEPTUM PERFORATION(2019-II*)

DRAW LABELLED DIAGRAM OF NASAL SEPTUM AND ITS BLOOD SUPPLY.ENUMERATE

CAUSES OF EPISTAXIS AND VARIOS METHODS OF NASAL PACKING(2022-I*)

ACUTE AND CHRONIC RHINITIS

42 | P a g e
ATROPHIC RHINITIS(2004-II,2010-II,2019-II,2013-II,2021-I)

MERCIFUL ANOSMIA(2019-I)

GRANULOMATOUS DISEASE OF NOSE

RHINOSPORIODOSIS(2008-II,2013-II,2016-II,2019-I,2010-I)

RHINOSCLEROMA(2007-I,2009-I,2018-II,2016-I,2021-II)

RHINITIS SICCA(2011-II,2017-I)

MISELLENAOUS DISEASE OF NASAL CAVITY

RHINOLITH(2007-II,2021-I)

NASAL MIASIS(2009-II*,2013-I,2018-I)

CSF RHINORRHEA(2019-I)

MANAGEMENT OF UNILATERAL NASAL DISCHARGE(2010-II*)

RETAINED FOREIGN BODY NOSE IN CHILD(2013-II)

ALLERGIC RHINITIS
ALLERGIC RHINITIS-ETIOLOGY,MANAGEMENT(2021-II,2014-I,2005-I,2015-II)

VASOMOTOR AND OTHER FORMS OF NON ALLERGIC RHINITIS

VASOMOTOR RHINITIS(2016-I)

RHINITIS MEDICAMENTOSA(2013-I)

NASAL POLYP
ETIOLOGY AND MANAGEMENT OF ETHMOIDAL POLYP(2006-I*)

43 | P a g e
D/D OF UNILATERAL MASS IN NASAL CAVITY(2007-I,2021-I*)

ANTROCHONAL POLYP(2009-I*,2012-II,2018-II)

DIFFERNCE BETWEEN ANTROCHOANAL AND ETHMOIDAL POLYP(2010-II,2011-II,2022-I*)

D/D OF UUNILATERAL NASAL DISCHARGE(2004-II)

EPISTAXIS
TREATMENT OF EPISTAXIS(2004-II,2006-I,2007-II,2014-I,2011-I*,2013-I*,2017-II)

ANATOMY OF KIESSELBECH PLEXUS(2008-I*,2013-II)

ETIOLOGY AND MANAGEMENT OF NASAL BLEEDING(2021-II*)

TRAUMA TO FACE
FRACTURE OF NASAL BONE(2008-I,2018-I)

TRIPOID FRACTURE(2018-I,2020-II)

BLOW OUT FRACTURE OF ORBIT(2012-I)

ANATOMY AND PHYSIOLOGY OF PARANASAL SINUSES

SURGICAL ANATOMY OF MAXILLARY SINUS(2007-I*)

CHRONIC SINUSITIS
MANAGEMENT OF CHRONIC MAXILLARY SINUSITIS(2008-II*)

COMPLICATION OF SINUSITIS
INTRACRANIAL COMPLICATION OF SINUSITIS(2009-II)

FRONTO ETHMOIDOCELE(2016-I)

44 | P a g e
 BENIGN AND MALIGNANT NEOPLASM OF NASAL CAVITY
INVERTED PAPILLOMA(2008-I,2010-I,2012-I*)

NEOPLASM OF PARANASAL SINUS

CARCINOMA MAXILLA -SIGNS AND SYMPTOMS(2007-II,2006-I)

CLINICAL STAGING OF CARCINOMA MAXILLA(2011-I,2004-II)

RINGERTZ TUMOUR(2010-I,2012-I*)

DISEASES OF ORAL CAVITY AND SALIVARY GLAND

ORAL SUBMUCOUS FIBROSIS(2004-II,2012-I,2013-II,2018-II)

WALDEYERS RING(2008-II)

RANULA(2022-I)

LEUKOPLAKIA(2005-I,2012-II)

TONGUE TIE(2021-I)

NON HEALING ULCER OF TONGUE(2017-II)

BENIGN TUMOURS OF ORAL CAVITY(2020-II)

APTHOUS ULCER(2009-II)

PREMALIGNANT LESION OF ORAL CAVITY(2021-II)

45 | P a g e
 PHARYNX
QUINSY/PERITONSILLAR ABSCESS(2007-I,2009-I*,2015-I,2016-II,2021-II,2012-II,2019-
II*,2020-II)

LUDWIG ANGINA(2007-I,2016-II,2021-II,2012-II)

ADENOID FACIES(2009-I,2016-I,2019-I,2007-I,2013-I)

TRISMUS(2005-I)

RETROPHARYNGEAL ABSCESS(2016-I,2017-I,2018-I,2007-I,2009-II,2017-I)

ZENKER DIVERTICULUM(2008-I)

TONSIL VS ADENOIDS(2011-II)

CHRONIC ADENO TONSILLITIS(2011-I)

ANATOMY OF PALATINE TONSIL(2014-I*)

OBSTRUCTIVE SLEEP APNEA(2015-II)

VINCENT ANGINA(2016-II)

DIPTHERIA(2017-I)

KILLIAN DEHISCENCE(2018-II)

D/D OF WHITE PATCH ON TONSIL(2017-II)

EAGLE SYNDROME(2013-I)

LARYNX AND TRACHEA

TRACHEOSTOMY(2008-II,2011-II,2015-I,2015-II,2017-I,2019-II,2019-I*)

INDICATION OF TRACHEOSTOMY(2009-II,2010-I)

VOCAL NODULE(2005-I*,2007-II,2009-I,2013-II,2015-II,2016-I,2018-I,2022-I)

ADVANTAGES AND DISADVANTAGES OF TRACHEOSTOMY(2014-I,2022-I*)

POST OPERATIVE CARE OF TRACHEOSTOMY(2007-I)

PHYSIOLOGY OF PHONATION(2007-I*,2008-II*,2012-I)

46 | P a g e
STRIDOR(2006-I,2009-I,2014-I,2016-I)

D/D OF STRIDOR IN CHILD(2004-II)

REINKE OEDEMA(2008-II)

VOICE DISORDER(2011-I,2013-I)

ACUTE EPIGLOTTITIS(2008-I,2019-II,2012-II*)

LARYNGOMALACIA(2016-I,2018-II)

VOCAL CORD PALSY(2014-I,2014-II*)

LARYNGOCELE(2016-II)

LARYNGEAL WEB(2021-I)

INTRINSIC MUSCLES OF LARYNX(2004-II*,2015-I*)

CAUSES OF HOARSENESS OF VOICE AND ITS MANAGEMENT(2011-II*,2016-II*)

LARYNGEAL CARTILAGES(2018-I*)

THYROID
BLOOD SUPPLY OF THYROID GLAND(2011-II)

COMPLICATION OF THYROIDECTOMY(2015-I)

EVALUATION OF THYROID NODULE(2015-II)

THYROPLASTY(2019-I)

OESOPHAGUS
PLUMMER VINSON SYNDROME(2012-II,2013-II*,2019-II,2020-II*,2022-I)

PHYSIOLOGY OF SWALLOWING/DEGLUTITION AND CAUSES OF DYSPHAGIA(2015-II*)

HIATUS HERNIA(2016-II)

PHYSIOLOGY OF DEGLUTITION(2018-I*,2007-II*,2011-I)
PHYSIOLOGY OF DEGLUTITION ANDC/F OF ACHALASIA CARDIA(2013-I*)

47 | P a g e
CLINICAL METHODS IN ENT AND NECK MASSES
THYROGLOSSAL CYST(2008-II,2010-II)

BRACHIAL FISTULA(2015-I,2017-II)

MIDLINE NECK SWELLING(2017-I)

D/D OF IDLINE NECK SWELLING AND C/F ,MX OF THYROGLOSSAL CYST(2012-I*)

TRIANGLES OF NECK(2010-II)

NECK DISSECTION(2014-II)

JUGULODIGASTRIC LYMPH NODE(2017-II)

SURGICAL PROCEDURES
MYRINGOTOMY(2005-I,2010-II,2012-I,2015-I*,2019-I,2022-I)

COMPLICATIONS OF TONSILLECTOMY(2018-I,2021-I*,2007-II)

REACTIONARY HAEMORRHAGE FOLLOWING TONSILLECTOMY(2010-I*)

BRONCHOSCOPY(2006-I,2014-II,2021-I)

CORTICAL MASTOIDECTOMY(2009-I,2015-I)

STROBOSCOPY(2016-I*,2018-II)

COMPLICATIONS OF SMR(2005-I)

FESS(2014-II)

ENDONASAL DCR(2014-II)

DIAGNOSTIC NASAL ENDOSCOPY(2020-II)

SEPTOPLASTY VS SMR(2019-I*)

SEPTOPLASTY-INDICATIONS AND COMPLICATIONS(2006-I)

ANTRAL PUNCTURE VS INTRANASAL ANTROSTOMY(2011-I)

48 | P a g e
FORENSIC MEDICINE AND
TOXICOLOGY

49 | P a g e
FORENSIC MEDICINE
INQUEST(2005-I,2008-I,2015-II,2017-II,2010-I)

DEFINE IQUEST AND ITS TYPES .ACCOUNT ON CRIMINAL COURTS AND THEIR POWERS(2018-
I*)

TYPES OF COURT IN INDIA .DESCRIBE POWER OF JUDICIAL MAGISTRATE AND SESSION

COURTS(2018-II)

FUNCTIONS OF MCI(2005-I,2008-II,2014-II,2017-I*)

INFLAMOUS CONDUCT(2010-II,2012-I*)

DYING DECLARATION(2005-I,2006-II,2007-II,2009-II,2012-I,2015*-I,2016-II)

DYING DECLARATION AND DYING DEPOSITION(2019-I)

DUTIES OF REGISTERED MEDICAL PRACTITIONER(2005-I*)

CONSENT(2009-I*,2017-I)

DUTIES OF DOCTOR IN WITNESS BOX(2009-I)

CIVIL AND CRIMINAL NEGLIGENCCE(2012-I,2011-I,2018-I,2018-II*)

MEDICAL NEGLIGENCE(2013-I,2020-I)

DACTYLOGRAPHY/FINGER PRINT(2004-II,2005-II,2008-II,2010-II,2014-I,2015-II,2016-II,2017-
I,2018-I,2018-II,2019-II,2020-I)

MALE AND FEMALE PELVIS(2011-II)

PROFESIONAL MISCONDUCT(2009-II,2011-II,2013-II*,2015-I)

MEDICO LEGAL IMPORTANCE OF AGE OF 18 YEAR(2004-II,2008-II*)

MEDICO LEGAL IMPORTANCE OF AGES 10,12,16,21(2004-II*,2019-I*)

GREVIOUS HURT/IPC 320(2004-II,2006-I,2007-I,2008-I,2010-II,2011-II,2016-I,2018-I,2019-

I,2019-II,2014-I*)

ESTIMATION OF TIME SINCE DEATH(2004-I*,2013-I*,2014-II*)

TATOO MARKS(2005-I,2014-II)

ROLE OF FORENSIC DENTIST(2013-I)

SKULL FRACTURES(2016-I,2019-II)

50 | P a g e
DECOMPOSITION(2005-I)

CADAVERIC SPASM(2005-II,2010-I,2015-I)

INTRACRANIAL HAEMORRHAGES(2005-II,2007-I,2008-I)

EXHUMATION(2006-II,2016-I,2019-I)

CONTUSIONS(2008-II,2011-II)

ARTIFICIAL BRUISE(2009-I,2014-II)

LACERATED WOUND(2011-II)

RIGOR MORTIS(2004-II,2014-I)

CHANGES AFTER DEATH.WRITE ABOUT CONDITIONS RESEMBLING RIGOR MORTIS(2009-I*)

MEDICO LEGAL ASPECT OF SCAR(2015-II)

POST MOTERM LIVIDITY(2009-II,2011-II,2015-II*)

DEFINE DEATH AND ITS TYPES AND MEDICO LEGAL IMPORTANCE(2016-I*)

DEFINE DEATH.TYPES OF DEATH,MODE OF DEATH,MODE,MANNERS OF DEATH,PM

APPEARENCE(2018-II*,2019-II*,2011-I*)

DEFINE DEATH,ITS TYPES AND CRITERIA TO DIAGNOSE BRAIN DEATH(2005-I*)

CHANGES AFTER DEATH IN ASPECT TO IMMEDIATE CHANGES ,EARLY CHANGES ,LATE

CHANGES AND MEDICO LEGAL IMPORTANCE(2017-II*,2006-ii)

CHANGES AFTER DEATH.FEATURES OF PUTREFACTION(2019-I*,2020-I*)

ABRASIONS AND ITS TYPES .MEDICO LEGAL IMPORTANCE(2012-I,2015-I*)

ANTEMOTERM AND POSTMOTERM ABRASION(2011-I)

AGE OF ABRASION(2018-II)

STAB WOUND(2009-II)

FEATURE OF WOUND ENTRY OF RIFFLED FIREARM(2006-II)

DIFFERNCE BETWEEN ENTRY AND EXIT WOUNDIN RIFFLED ARM INJURIES(2004-II,2012-

I,2018-I,2008-II)

CLASSIFY FIREARM.DESCRIBE CONTACT WOUND BY BULLET ON HEAD(2010-I*)

CADAVERIC SPASM AND RIGOR MORTIS(2012-I)

51 | P a g e
RES ISPA LQQUITUR(2011-I)

CIRCLE OF WILLIS(2007-II)

RIOCHET BULLET(2018-I,2019-II)

GUN SHOT RESIDUES(2018-II)

MERCY KILLING(2012-II)

AGE OF INJURY FROM BRUISE(2017-I)

CLASSIFY MECHANICAL INJURIES(2014-I*)

HYDROSTATIC TEST(2006-I,2009-II,2011-II,2014-II)

DROWNING.TYPES, AND POST MOTERM FINDINGS(2007-I*,2008-I*,2009-II*,2010-II*,2013-

I*,2014-I*,2014-II,2016-II*,2018-I*,2019-II*,2017-I,2019-II)

BATTERED BABY SYNDROME(2007-I*,2012-I,2017-I,2017-II)

SUDDEN INFANT DEATH SYNDROME(2013-I)

CIVIL RESPONSIBILITY OF INSANE(2007-I,2007-II,2013-II,2018-II,2019-II,2020-I,2017-I)

POSITIVE SIGNS OF PREGNANCY(2008-I,2010-II,2015-II,2016-I*)

DIATOMS(2004-I,2006-I*,2014-I,2017-I)

INFANTICIDE(2006-II*,2007-II*)

HANGING-TYPES,POST MOTERM FINDING(2010-I*,2015-I*,2004-II)

PARTIAL HANGING(2009-I)

DIFFERNCE HANGING AND STRANGULATION(2019-I,2015-II*)

ANTEMOTERM AND POSTMOTERM HANGING(2011-I)

DEFINE AND CLASSIFY VARIOUS MECHANICAL ASPHYXIAL DEATHS AND AUTOPSY FINDINGS
OF DIFFERENT DIFFERENT TYPES OF MECHANICAL ASPHYXIAL DEATHS(2020-I*,2007-
II*,2012-II*)

POST MOTERM FINDING IN DEATH DUE TO LIGATURE STRANGULATION(2009-I*)

TRAUMATIC ASPHYXIA(2006-I*)

SEXUAL ASPHYXIA(2014-I)

52 | P a g e
CLASSIFY THERMAL INJURIED.APPEARENCE OF BURNS AS PER WILSON
CLASSIFICATION(2012-II*)

PUGILISTIC ATTITUDE(2013-I)

RULE OF NINE(2018-I,2019-II)

JOULE BURN(2019-I)

DIFFERNCE BETWEEN BURNS AND SCALDS(2008-I)

SIGNS OF ANTEMOTERM BURNS(2008-II,2009-II)

DIFFERENT CLASSIFICATION OF BURNS(2020-I)

DIFFERENCE BETWEEN FLAME BURN/MOIST BURN/COROSSIVE BURN(2013-II*)

POST MOTERM FINDING IN DEATH DUE TO BURNS AND MEDICO LEGAL IMPORTANCE(2015-
II*,2004-I*)

TRUE AND FALSE INSANITY(2010-II)

RAPE-EXAMINATION OF VICTIM OF RAPE AND FINDINGS AND MEDICOLEGAL

IMPORTANCE(2004-I*,2005-II*,2008-I*,2009-II*,2011-II*)

IPC 375(2006-II,2013-II,2014-II*)

SECTION 376 IPC AS PER RECENT AMENDMENT(2020-I)

MTP(2004-II*,2005-II,2007-I,2008-II,2014-II,2016-I)

DEFINE ABORTION.VARIOUS METHODS USED FOR INDUCING CRIMINAL ABORTION AND ITS
COMPLICATIONS(2010-I*,2015-I,2007-II)

DEFINE VIRGINITY.SIGNS OF VIRGINITY(2006-I*)

SODOMY(2013-I)

IMPOTENCE(2012-II)

HOMICIDE AND DOWRY DEATH(2017-II)

HALLUCINATIONS(2005-II,2014-I,2007-II)

DELUSIONS(2015-I,2017-II)

McNAUGHTEN RULE(2012-I)

ARTIFICIAL INSEMINAYION(2017-II,2010-I)

53 | P a g e
TOXICOLOGY
CLASSIFY POISONS(2015-I*)

GASTRIC LAVAGE-CONTRAINDICATIONS AND INDICATION(2004-I,2008-II,2007-II,2009-

II,2010-II)

ANTIDOTE-CLASSIFICATION,TYPES(2007-II*,2010-I,2014-I)

MECHANICAL ANTIDOTE(2009-I,2014-II,2015-II)

CHEMICAL ANTIDOTES(2006-I)

CHELATING AGENTS(2005-II,2006-II)

DIFFERNCE BETWEEN POISOINOUS AND NON POISOINUS SNAKE (2015-I,2016-II,2018-

I,2011-II)

CLASSIFY INDIAN POISOINOUS SNAKES BASED ON THEIR VENOM(2020-I)

ANTI SNAKE VENOM(2006-I,2010-I)

GENERAL LINE TREATMENT OF UNKNOWN POISOINING(2005-I*,2020-I*,2013-II*)

ALUMINIUM PHOSPHIDE POISOINING-TREATMENT(2008-I)

ORGANOPHOSPHORUS POISOINING-MOA,SIGNS ,SYMPTOMS,TREATMENT,MEDICO LEGAL

IMPORTANCE(2005-II,2006-II*,2010-II,2014-II,2016-I*,2016-II*,2019-I*,2019-II*,2009-
II,2020-I)

LEAD POISOINING-SIGNS,SYMPTOMS,TREATMENT(2004-I,2018-I*,2014-II,2018-II*,2010-
I,2013-II,2015-I)

ACUTE POISOINING DUE TO CORROSIVE SUBSTANCE(2005-I)

54 | P a g e
ABRUS PRECATORIUS(2009-II)

DRUNKENESS(2005-I)

METHYL ALCOHOL POISOINING-SIGNS,SYMPTOMS ,TREATMENT(2008-II*,2004-II,2005-

II,2007-I*,2018-II,2019-II)

ALCOHOL WITHDRAWL SYNDROME(2020-I)

POISOINOUS SNAKE BITE-TREATMENT(2004-II,2008-I*)

DHATURA POISOINING-SIGNS,SYMPTOMS,TREATMENT(2004-I,2011-II*,2013-II,2014-
I*,2015-II,2019-I,2005-I,2006-I)

DHATURA AND CAPSICUM SEEDS(2010-II)

COCAINE(2006-II,2009-I)

STRYNCHNINE POISOINING VS TETANUS(2007-I,2011-I,2012-I)

ACONITE(2009-I)

DIFFERNCE DRUG ADDICTION AND DRUG HABITUATION(2014-I)

BROWN SUGAR(2017-I)

ACID AND ALKALI POISOINING(2010-II)

ARSENIC POISOINING(2006-II,2016-I)

CYANIDE POISOINING-SIGNS,SYMPTOMS,TREATMENT(2004-I,2006-I*)

CARBON MONOXIDE POISOINING-SIGNS,SYMPTOMS ,TREATMENT(2011-I)

55 | P a g e